beta
Trial Radar AI
Clinical Trial NCT07490236 for Trilaciclib, CDK4/6-dependent Solid Tumors is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors Phase 1 100 First-in-Class Real-World Evidence

Recruiting
Clinical Trial NCT07490236 is designed to study Prevention for Trilaciclib, CDK4/6-dependent Solid Tumors. It is a Phase 1 interventional study that is recruiting, having started on 1 January 2023, with plans to enroll 100 participants. Led by Hebei Medical University Fourth Hospital, it is expected to complete by 1 August 2028. The latest data from ClinicalTrials.gov was last updated on 24 March 2026.
Brief Summary
Trilaciclib, an innovative first-in-class therapy that protects bone marrow at the source, has been approved for use in CDK4/6-independent small-cell lung cancer. However, clinical practice shows that patients with solid tumors frequently experience treatment-related pancytopenia involving neutrophils, erythroid lineage, and platelets after antineoplastic therapy, with a particularly high incidence of grade 3-4 myelo...Show More
Official Title

Exploration of Indications and Establishment of a Primary Prevention Prediction Model for Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors, and Investigation of the Mechanisms of Related Influencing Factors

Conditions
TrilaciclibCDK4/6-dependent Solid Tumors
Other Study IDs
  • G1T28-T-001
NCT ID Number
NCT07490236
Start Date (Actual)
2023-01-01
Last Update Posted
2026-03-24
Completion Date (Estimated)
2028-08-01
Enrollment (Estimated)
100
Study Type
Interventional
PHASE
Phase 1
Status
Recruiting
Primary Purpose
Prevention
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalTrilaciclib+chemotherapy
Trilaciclib group
Trilaciclib+chemotherapy
No Interventionchemotherapy
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Incidence of grade 3-4 myelosuppression
Within 4 weeks after completion of chemotherapy
Participation Assistant
Eligibility Criteria

Eligible Ages
Child, Adult, Older Adult
Eligible Sexes
All
  • patients for whom primary prophylaxis with trilaciclib is indicated per Model A will receive primary prophylactic treatment.

  • patients for whom primary prophylaxis with trilaciclib is not indicated per Model A will receive secondary prophylaxis according to protocol.
Hebei Medical University Fourth Hospital logoHebei Medical University Fourth Hospital
No contact data.
1 Study Locations in 1 Countries

Hebei

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050300, China
JIAN SHI, PhD, Contact, 0311 - 86095588, [email protected]
Recruiting